GlassScriptPhysician profile
Carl W Dobson
NPI 1972505527
$6,129.07
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,238 · 2020: $498 · 2021: $1,433 · 2022: $1,471 · 2023: $1,235 · 2024: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.57 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $1,020.87 | 2020-2024 | Ova1 |
| Abbvie INC. | $902.16 | 2019-2023 | Ubrelvy, Qulipta, Orilissa |
| Amgen INC. | $699.97 | 2019-2023 | Prolia, Evenity |
| Astellas Pharma US INC | $374.18 | 2019-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $274.09 | 2021-2023 | |
| Allergan, INC. | $220.47 | 2019 | |
| Caldera Medical, INC | $216.33 | 2023 | Desara |
| Pfizer INC. | $173.19 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $171.13 | 2021 | |
| Novo Nordisk INC | $153.41 | 2019-2023 | Wegovy, Saxenda |
| Pacira Pharmaceuticals Incorporated | $142.37 | 2021 | |
| Myovant Sciences INC. | $133.46 | 2021-2022 | |
| Exeltis, USA INC. | $116.75 | 2021-2023 | Slynd |
| Daiichi Sankyo INC. | $116.75 | 2019-2024 | Injectafer |
| Channel Medsystems, INC. | $106.42 | 2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Dobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.